Skip to Content

COVID-19 Info: Please help us slow the spread of coronavirus - Wear a Mask, Wash Your Hands & Wait 6 Feet Apart!
Visitor Policies and Precautions | COVID-19 Testing| Vaccine information | Commitment to Safety | Current Numbers

Clinical Trials Search Results

Showing 1-4 of 4

Sorted By:

  • Lung Map

    A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

  • Merck MK7902-007

    A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1%.

  • SWOG S1400F

    A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated ANTI-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study).

  • SWOG S1900A

    A Phase II Study of Rucaparib in Patients with Genomic LOH High And/Or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study).